osimertinib
astrazeneca
['lcsm,(-blcsm)', 'lung']
this multi institutional study of neoadjuvant osi in early stage #egfrm #lungcancer it did not meet primary endpoint (mpr 50%) but much to learn from other endpoints , importantly resistance is a problem in both early and late stage. #lcsm #asco23 
Lung Cancer Patient and Advocate, Co-Founder @EGFRResisters, wife, mom of 4, #LCSM #lungcancer #HealthEquity #EndStigma #RockChalk
ASCO FCOI:https://t.co/B3LsDv6XSu